Tham side effects, by duration, gender and age (a phase IV clinical study of FDA data)

female:

1. Cardiac arrest
2. Cardiac arrest neonatal
3. Disseminated intravascular coagulation (systemic activation of blood coagulation)
4. Hyperthermia (body temperature greatly above normal)
5. Medical device complication
6. Anxiety
7. Bone pain
8. Acute hepatic failure
9. Abdominal pain upper
10. Blood ph decreased

male:

1. Cardiac arrest
2. Cardiopulmonary failure (cessation of normal circulation of the blood due to failure of the heart to contract)
3. Circulatory collapse
4. Drug ineffective
5. Electroencephalogram abnormal

0-1:

1. Blood ph decreased
2. Cardiac arrest
3. Cardiopulmonary failure (cessation of normal circulation of the blood due to failure of the heart to contract)
4. Drug ineffective
5. Medical device complication

2-9:

1. Cardiac arrest
2. Electroencephalogram abnormal

10-19:

1. Cardiac arrest neonatal

20-29:

n/a

30-39:

n/a

40-49:

1. Hyperthermia (body temperature greatly above normal)
2. Anxiety

50-59:

1. Anxiety

60+:

1. Acute hepatic failure
2. Disseminated intravascular coagulation (systemic activation of blood coagulation)

< 1 month:

1. Disseminated intravascular coagulation (systemic activation of blood coagulation)

1 - 6 months:

n/a

6 - 12 months:

n/a

1 - 2 years:

n/a

2 - 5 years:

n/a

5 - 10 years:

n/a

10+ years:

n/a

not specified:

1. Anxiety
2. Circulatory collapse
3. Drug ineffective
4. Electroencephalogram abnormal
5. Hyperthermia (body temperature greatly above normal)
6. Medical device complication
7. Peripheral ischaemia (impaired circulation to an extremity)
8. Bone pain
9. Cardiac arrest
10. Acute hepatic failure